The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 Juyou Bio-Technology Co.,

Licensing 40

Licensing Licensing Dermatology Production 40

Drug Discovery World

JULY 10, 2023

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. As a result, model generation is an attractive option often considered in parallel.

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

The Pharma Data

SEPTEMBER 8, 2020

The safety and efficacy of vaccines, including any potential vaccine for COVID-19, is reviewed and determined by expert regulatory agencies around the world, such as the United States Food and Drug Administration (FDA). For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn. Sanofi, Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

SEPTEMBER 8, 2020

United States Food and Drug Administration. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. This press release contains “forward-looking statements” of. For more information, visit. www.novavax.com. and connect with us on.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

License-related fees (5). License-related fees (5). Food and Drug Administration (FDA) in support of an efficacy supplement to the Tyvaso new drug application (sNDA), which we expect to result in revised labeling reflecting the outcome of the INCREASE study.

Production 40

Production Sales Licensing Licensing 40